Franchise opportunities compared

    Galt Pharmaceuticals vs Hommati

    Reviewed figures from each brand's Franchise Disclosure Document (FDD), side by side. Each figure carries its FDD year and page. This is not a ranking or recommendation, and the two FDDs may cover different years and location groups.

    Initial investment · Item 7

    Galt Pharmaceuticals

    $122,350 – $348,700

    2026 FDD · Item 7 · PDF p. 21

    Hommati

    $39,872 – $74,223

    2026 FDD · Item 7

    Initial franchise fee · Item 5

    Galt Pharmaceuticals

    $100,000

    2026 FDD · Item 5 · PDF p. 13

    Hommati

    Not available

    Royalty · Item 6

    Galt Pharmaceuticals

    Not available

    Hommati

    8%

    2026 FDD · Item 6 · PDF p. 12

    Before you compare

    • Both sets of figures come from 2026 FDDs.
    • Hommati discloses more than one business format, so the investment range spans formats; the full report breaks them out.
    • Item 19 figures cover the location groups each FDD names (Galt Pharmaceuticals: 4, Hommati: 18). Different groups are not directly comparable.

    Financial commitment

    Estimated initial investment (Item 7)

    Galt Pharmaceuticals

    $122,350 – $348,700
    Total initial investment: $122,350 to $348,700
    2026 FDD · Item 7 · PDF p. 21

    Hommati

    $39,872 – $74,223
    2026 FDD · Item 7
    Standard initial franchise fee (Item 5)

    Galt Pharmaceuticals

    $100,000
    The FDD also lists a past-fiscal-year initial franchise fee range of $125,000 to $300,000.
    2026 FDD · Item 5 · PDF p. 13

    Hommati

    Not available
    No single standard fee identified
    Royalty (Item 6)

    Galt Pharmaceuticals

    Not available
    No reviewed royalty record

    Hommati

    8%
    Royalty rate on monthly Gross Revenues
    2026 FDD · Item 6 · PDF p. 12
    Brand / advertising fund (Item 6)

    Galt Pharmaceuticals

    $1,000
    Marketing Fee maximum: $1,000 per month per territory
    2026 FDD · Item 6 · PDF p. 15

    Hommati

    4%
    National Advertising Fund maximum — 4%
    2026 FDD · Item 6 · PDF p. 13

    System scale & health

    Total outlets (Item 20)

    Galt Pharmaceuticals

    63
    Outlets at end of 2025
    2026 FDD · Item 20 · PDF p. 48

    Hommati

    117
    Outlets at end of 2025
    2026 FDD · Item 20 · PDF p. 50
    Net outlet change (Item 20)

    Galt Pharmaceuticals

    −3
    Calculated: 66 at end of 2023 → 63 at end of 2025

    Hommati

    −19
    Calculated: 136 at end of 2023 → 117 at end of 2025
    Outlet exits (Item 20)

    Galt Pharmaceuticals

    0
    Closures, terminations & non-renewals in 2025 · Calculated turnover 0.0% of outlets at start of year
    2026 FDD · Item 20 · PDF p. 48

    Hommati

    Not available
    No complete exit records for a year
    Franchising since (Item 1)

    Galt Pharmaceuticals

    Not available
    Not in reviewed records

    Hommati

    Not available
    Not in reviewed records
    Franchisor founded (Item 1)

    Galt Pharmaceuticals

    Not available
    Not in reviewed records

    Hommati

    Not available
    Not in reviewed records

    Financial performance (Item 19), by location group

    Galt Pharmaceuticals
    Locations counted not stated in the reviewed record — Bottom third of 24 Operational Franchise Outlets; reporting period 2025.
    $12,142
    other Bottom third
    2026 FDD · Item 19 · PDF p. 46
    Locations counted not stated in the reviewed record — Middle third of 24 Operational Franchise Outlets; reporting period 2025.
    $66,763
    other Middle third
    2026 FDD · Item 19 · PDF p. 46
    Locations counted not stated in the reviewed record — Top third of 24 Operational Franchise Outlets; reporting period 2025.
    $813,752
    other Top third
    2026 FDD · Item 19 · PDF p. 46
    +1 more groups in the full report
    Hommati
    Locations counted not stated in the reviewed record — Hommati franchise network
    108 franchisees
    other Network size at survey
    2026 FDD · Item 19 · PDF p. 45
    Locations counted not stated in the reviewed record — Full-Time Franchisees; AVERAGE stated results
    $129,723
    other full-time annual gross profit
    2026 FDD · Item 19 · PDF p. 47
    Locations counted not stated in the reviewed record — Full-Time Franchisees; LOWEST stated results
    $33,537
    other LOWEST full-time annual gross revenues
    2026 FDD · Item 19 · PDF p. 47
    +15 more groups in the full report

    Item 19 groups are shown separately and never combined. Revenue or sales figures are not profit. Net outlet change and turnover are Franopolis calculations from the disclosed counts; turnover is a count-based rate, not a measure of owner earnings.

    Galt Pharmaceuticals vs Hommati: common questions

    Which costs less to open, Galt Pharmaceuticals or Hommati?
    Galt Pharmaceuticals: $122,350 – $348,700 (2026 FDD · Item 7 · PDF p. 21); Hommati: $39,872 – $74,223 (2026 FDD · Item 7). These are each franchisor's Item 7 estimated initial investment. The low end of the disclosed estimate is lower for Hommati. At least one range spans several business formats. Estimates are not quotes, and the FDD years may differ.
    Which has more locations, Galt Pharmaceuticals or Hommati?
    Galt Pharmaceuticals: 63 (2026 FDD · Item 20 · PDF p. 48); Hommati: 117 (2026 FDD · Item 20 · PDF p. 50). Total outlets from Item 20. Outlet counts do not indicate territory availability or franchisee results.
    Do Galt Pharmaceuticals and Hommati disclose financial performance (Item 19)?
    Galt Pharmaceuticals has reviewed Item 19 figures for 4 location groups; Hommati has reviewed Item 19 figures for 18 location groups. Different location groups are not directly comparable, and revenue is not profit.

    Answers restate the reviewed figures above. Not a ranking or recommendation.

    How Franopolis reviews FDD figures

    Keep researching